Health ProductsDear Healthcare Professional Letter

Pradaxa/Pradax (dabigatran etexilate) - New Contraindication in Patients with Prosthetic Heart Valves Requiring Anticoagulant Treatment Due to their Valvular Status - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Boehringer Ingelheim (Canada) Ltd. . Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

NOTE: This document should be read in conjunction with the Notice to Hospital issued by Health Canada, which provides additional important safety information regarding this issue.

Important Safety Information on Pradaxa/Pradax (dabigatran etexilate)

December 21, 2012

Dear Health Care Professional:

Subject: PradaxaTM/Pradax® (dabigatran etexilate): New contraindication in patients with prosthetic heart valves requiring anticoagulant treatment due to their valvular status

Boehringer Ingelheim (Canada) Ltd. (BICL), in consultation with Health Canada (HC), would like to inform you about important new safety information relating to the use of PradaxaTM (dabigatran etexilate), also known as Pradax®, in patients with prosthetic heart valves. Based on recent information, the PradaxaTM Product Monograph (PM) will be revised to include a new contraindication for use in patients with prosthetic heart valves requiring anticoagulant treatment due to their valvular status.

This change is based on interim results from a phase II trial (RE-ALIGN) which compared dabigatran etexilate and warfarin in a total of 252 patients with prosthetic heart valves.  The study investigated a dose range of 150 mg twice daily to 300 mg twice daily in patients with recent mechanical heart valve replacement surgery (within the current hospital stay) and in patients who received mechanical heart valve replacement more than three months before.  More thromboembolic events (mainly strokes, and symptomatic/asymptomatic prosthetic valve thrombosis) and more bleeding events were observed with dabigatran etexilate than with warfarin, especially in patients who were randomised post-surgery, i.e., soon after mechanical valve placement. As a result, Boehringer Ingelheim decided to discontinue the study and update the worldwide labelling to contraindicate the use of PradaxaTM in patients with prosthetic heart valves.

  • A 12-week open-label randomized study comparing dabigatran etexilate with warfarin was discontinued as a result of an interim analysis showing numerical excess of thrombosis, that included valve thrombosis, stroke and myocardial infarction in patients with recent mechanical heart valve placement receiving dabigatran.
  • PradaxaTM is now contraindicated for use in patients with prosthetic heart valves requiring anticoagulant treatment due to their valvular status.
  • Health care providers are reminded to strictly follow the recommended conditions of use for PradaxaTM.

BICL is working closely with HC to update the product label accordingly.

PradaxaTM (dabigatran etexilate) is an oral anticoagulant authorized for sale in Canada for the prevention of venous thromboembolic events in patients following hip or knee replacement surgery and  for the prevention of stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation is appropriate.Footnote 1 PradaxaTM is currently not recommended for use in patients with prosthetic heart valves, with or without atrial fibrillation, see WARNINGS AND PRECAUTIONS, Cardiovascular, Patients with Valvular Disease of the current Product Monograph.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving PradaxaTM should be reported to Boehringer Ingelheim (Canada) Ltd, or to Health Canada:

Boehringer Ingelheim (Canada) Ltd.,

5180 South Service Rd. Burlington, ON, L7L 5H4

Tel: 1 (800) 263-5103 Ext. 87233.

To correct your mailing address or fax number, contact Boehringer Ingelheim (Canada) Ltd.

To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffectTM Canada Web site for information on how to report.

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.

For other health product inquiries related to this communication, please contact Health Canada at:

Marketed Health Products Directorate

E-mail: mhpd_dpsc.public@hc-sc.gc.ca

Telephone: 613-954-6522

Fax: 613-952-7738

The PradaxaTM Product MonographFootnote 1 as well as a copy of this letter can be found on the Boehringer Ingelheim (Canada) Ltd., website.

Sincerely,

original signed by

Mathias Knecht, M.D.

Vice President, Medical and Regulatory Affairs

Boehringer Ingelheim (Canada) Ltd.

References:

Footnotes

Footnote 1
1. PradaxaTM Product Monograph, dated November 28, 2012

 

Return to footnote 1 referrer

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime